CMOPF (Cosmo NV) Total Equity: $572.8 Mil (As of Dec. 2025)


CMOPF Cosmo NV CMOPF
82 GF Score
Price $82.00
GF Value $53.54
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cosmo NV Total Equity?

Cosmo NV CMOPF -3.22% 82 Total Equity is $572.8 Mil as of Dec. 2025. GuruFocus rates CMOPF with a GF Score™ of 82/100 and a GF Value™ of $53.54 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Cosmo NV's total equity for the quarter that ended in Dec. 2025 was $572.8 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Cosmo NV Total Equity Historical Data

* Premium members only.

The historical data trend for Cosmo NV's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosmo NV Total Equity Chart

Cosmo NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 579.30 491.30 440.16 528.89 572.81

Cosmo NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 440.16 544.01 528.89 538.61 572.81
CMOPF
82GF Score
Cosmo NV CMOPF
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cosmo NV Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Cosmo NV's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=717.374-144.564
=572.8

Cosmo NV's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=717.374-144.564
=572.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $572.8 Mil mean?
Cosmo NV (CMOPF) has a Total Equity of $572.8 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Cosmo NV and its competitors.
Is Cosmo NV's Total Equity too high?
Cosmo NV's current Total Equity is $572.8 Mil. Overall, Cosmo NV has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's Total Equity compare to LLY and JNJ?
Cosmo NV's Total Equity of $572.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Cosmo NV and its competitors. Cosmo NV's current Total Equity is $572.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (CMOPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $53.54, compared to a current price of $82.00 — trading 53.2% above its estimated fair value. The current Total Equity is $572.8 Mil. Cosmo NV's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Cosmo NV (CMOPF), the current Total Equity is $572.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cosmo NV (CMOPF) Overvalued in 2026?

Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued. The current stock price of $82.00 is trading 53.2% above its estimated GF Value™ of $53.54. GuruFocus considers Cosmo NV to be Significantly Overvalued.

Key valuation signals for CMOPF:

  • Total Equity: $572.8 Mil
  • GF Value™: $53.54 vs. price of $82.00 (53.2% above fair value)
  • GF Score™: 82/100 with 3 warning signs

No single metric tells the full story. See the CMOPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosmo NV Business Description

Address 91/94 North Wall Quay, 7th Floor, One North Dock, Dublin, IRL, D01 H7V7
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
82GF Score

Get the complete analysis for CMOPF

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$82.00
Price
$53.54
GF Value